Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

v3.7.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
3 Months Ended 6 Months Ended
Apr. 30, 2017
Apr. 30, 2016
Apr. 30, 2017
Apr. 30, 2016
Revenue
Operating costs and expenses:        
Litigation and licensing expenses 225 15,521 2,346 75,162
Amortization of patents 81,324 81,324 162,648 162,648
Research and development expenses (including non-cash stock option compensation expenses of $68,928, $72,496, $148,628 and $91,442, respectively) 431,124 392,589 882,754 850,910
Marketing, general and administrative expenses (including non-cash stock option compensation expenses of $122,991, $144,758, $303,028 and $238,307, respectively) 699,345 658,953 1,559,230 1,532,106
Total operating costs and expenses 1,212,018 1,148,387 2,606,978 2,620,826
Loss from operations (1,212,018) (1,148,387) (2,606,978) (2,620,826)
Gain on extinguishment of patent acquisition obligation (Note 6) 1,547,608 1,547,608
Interest expense (175,727) (126,980) (371,026) (250,881)
Interest income 626 3,473 1,625 6,724
Income (loss) before income taxes 160,489 (1,271,894) (1,428,771) (2,864,983)
Provision for income taxes
Net income (loss) 160,489 (1,271,894) (1,428,771) (2,864,983)
Deemed dividend to preferred stockholder (Note 7) (2,008,775)
Net loss attributable to common stockholders $ 160,489 $ (1,271,894) $ (3,437,546) $ (2,864,983)
Net income (loss) per common share:        
Basic (in Dollars per share) $ 0.02 $ (0.15)
Diluted (in Dollars per share) 0.02 (0.15)
Basic and diluted (in Dollars per share) $ (0.37) $ (0.33)
Weighted average common shares outstanding:        
Basic (in Shares) 9,734,171 8,736,024
Diluted (in Shares) 9,736,571 8,736,024
Basic and diluted (in Shares) 9,236,351 8,731,489